Exact Sciences Corporation $EXAS is Spyglass Capital Management LLC's 2nd Largest Position

Got story updates? Submit your updates here. ›

Spyglass Capital Management LLC, an investment management firm, grew its position in Exact Sciences Corporation (NASDAQ:EXAS) by 56.4% during the third quarter. The fund now owns 2,125,435 shares of the medical research company's stock, making it Exact Sciences' second-largest shareholder and accounting for 6.2% of Spyglass' portfolio.

Why it matters

Exact Sciences is a leading molecular diagnostics company focused on the early detection and prevention of cancer. The significant increase in Spyglass Capital's stake suggests the investment firm sees strong growth potential in Exact Sciences' business and products, such as its flagship Cologuard colorectal cancer screening test.

The details

According to a regulatory filing, Spyglass Capital Management acquired an additional 766,772 shares of Exact Sciences in the third quarter, bringing its total position to 2,125,435 shares. This represents approximately 1.12% of Exact Sciences' outstanding shares and makes the stock Spyglass' second-largest holding, behind only Teladoc Health. The investment firm cited Exact Sciences' market leadership in the cancer screening space and its potential for continued growth as reasons for increasing its stake.

• Spyglass Capital Management increased its position in Exact Sciences during the third quarter of 2025.